Coherus Oncology (CHRS) Total Liabilities (2012 - 2026)

Coherus Oncology has disclosed Total Liabilities across 15 years of filings, most recently posting $130.3 million for Q2 2026.

• In Q2 2026, Total Liabilities fell 59.22% year-over-year to $130.3 million; the TTM figure through Jun 2026 stood at $130.3 million (down 59.22% YoY), while the FY2025 annual figure was $197.3 million, down 66.01% from the prior year.
• Total Liabilities came in at $130.3 million for Q2 2026 at Coherus Oncology, down from $187.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $845.4 million in Q1 2024 to a low of $130.3 million in Q2 2026.
• Average Total Liabilities over 5 years is $544.2 million, with a median of $586.9 million recorded in 2022.
• Year-over-year, Total Liabilities surged 41.15% in 2024 and sank 66.21% in 2026.
• Over 5 years, Total Liabilities stood at $618.3 million in 2022, then surged by 33.12% to $823.0 million in 2023, then fell by 29.47% to $580.5 million in 2024, then sank by 66.01% to $197.3 million in 2025, then tumbled by 33.95% to $130.3 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $130.3 million in Q2 2026, $187.4 million in Q1 2026, and $197.3 million in Q4 2025.